{
    "clinical_study": {
        "@rank": "1535", 
        "acronym": "POM", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "An endotoxin challenge will be administered to healthy subjects to induce production of\n      inflammatory markers.  An investigational drug or placebo will be administered prior to the\n      endotoxin challenge to assess the effect of the investigational drug on the markers of\n      inflammation. Safety and tolerability will also be assessed."
        }, 
        "brief_title": "A Study To Evaluate The Safety And Effects On The Body Of An Investigational Drug Using An Endotoxin-Induced Inflammatory Response Model", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy men or women (non-childbearing potential) between the ages of 18-40 years.\n\n          -  Body Mass Index (BMI) 18-30 kg/m2 and a total body weight >50 kg (110 lbs).\n\n        Exclusion Criteria:\n\n          -  History or evidence of habitual use of tobacco- or nicotine-containing products\n             within 3 months of screening.\n\n          -  History of frequent headaches or migraines (>3 per month), or headaches from an\n             absence of caffeine.\n\n          -  Caffeine consumption in excess of 3 cups per day.\n\n          -  Subjects who have experienced cold/flu symptoms (ie, runny nose, cough, and/or fever)\n             within 2 weeks of the first administration of study drug/placebo of each period.\n\n          -  History of recurrent or chronic infections of any type such as tuberculosis,\n             sinusitis, urinary tract infection, respiratory tract or dental (abscess) infection,\n             etc.  Also excluded are subjects with recurrent oral or genital herpes, recurrent\n             herpes zoster, or any infection otherwise judged by the investigator to have the\n             potential for worsening if enrolled in this study.\n\n          -  Treatment with LPS in the past 12 months and/or a history of an allergic type\n             reaction or known hypersensitivity to endotoxin at any time."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01965600", 
            "org_study_id": "B5211007"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cohort 1", 
                "description": "Tablet, 125 mg, TID, 3 days, 1 of 2 periods", 
                "intervention_name": "PF-06282999", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 1", 
                "description": "Tablet, 0 mg, TID, 3 days, 1 of 2 periods", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 1", 
                "description": "IV bolus, 4 ng/kg, 1 day, QD, 2 of 2 periods", 
                "intervention_name": "LPS", 
                "intervention_type": "Other", 
                "other_name": "Endotoxin"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "description": "Tablet, 500 mg, BID, 3 days, 1 of 2 periods", 
                "intervention_name": "PF-06282999", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "description": "Tablet, 0 mg, BID, 3 days, 1 of 2 periods", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "description": "IV bolus, 4 ng/kg, 1 day, QD, 2 of 2 periods", 
                "intervention_name": "LPS", 
                "intervention_type": "Other", 
                "other_name": "Endotoxin"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Endotoxin challenge", 
        "lastchanged_date": "May 15, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B5211007&StudyName=A%20Study%20To%20Evaluate%20The%20Safety%20And%20Effects%20On%20The%20Body%20Of%20An%20Investigational%20Drug%20Using%20An%20Endotoxin-Induced%20Inflammatory%20Response%20Mod"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27710"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, 2-Way Crossover Study To Evaluate The Safety And Pharmacodynamic Effects Of PF-06282999 Using An Endotoxin (Lipopolysaccharide) Induced Inflammatory Response Model In Healthy Adult Subjects", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Day 3 timepoints are post-LPS administration", 
            "measure": "MPO activity", 
            "safety_issue": "No", 
            "time_frame": "Day 1 Hr 0; Day 3 Hr 0, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 4.5, 5, 5.5, 6, 8, 10, 12, 24, 48"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01965600"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "TNF-alpha", 
                "safety_issue": "No", 
                "time_frame": "Day 1 Hr 0; Day 3 Hr 2, 3, 4, 5, 6, 10, 24"
            }, 
            {
                "measure": "IL-1beta", 
                "safety_issue": "No", 
                "time_frame": "Day 1 Hr 0; Day 3 Hr 2, 3, 4, 5, 6, 10, 24"
            }, 
            {
                "measure": "IL-6", 
                "safety_issue": "No", 
                "time_frame": "Day 1 Hr 0; Day 3 Hr 2, 3, 4, 5, 6, 10, 24"
            }, 
            {
                "measure": "IL-8", 
                "safety_issue": "No", 
                "time_frame": "Day 1 Hr 0; Day 3 Hr 2, 3, 4, 5, 6, 10, 24"
            }, 
            {
                "measure": "hs-CRP", 
                "safety_issue": "No", 
                "time_frame": "Day 1 Hr 0; Day 3 Hr 8, 24"
            }, 
            {
                "measure": "MPO activity/MPO mass", 
                "safety_issue": "No", 
                "time_frame": "Day 1 Hr 0; Day 3 Hr 0, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 4.5, 5, 5.5, 6, 8, 10, 12, 24, 48"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Day 3 Hr 0, 2, 3, 4, 5, 6, 8, 12"
            }, 
            {
                "measure": "Area Under the Curve from Time Zero to end of dosing interval (AUCtau)", 
                "safety_issue": "No", 
                "time_frame": "Day 3 Hr 0, 2, 3, 4, 5, 6, 8, 12"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "Day 3 Hr 0, 2, 3, 4, 5, 6, 8, 12"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}